Massachusetts Draws a Hard Line on THC Labels With New Potency Audits

Massachusetts sets a hard THC band and attaches real enforcement to it

Massachusetts has moved a common industry complaint into an enforceable rule. In a bulletin issued on May 22, the Cannabis Control Commission said a cannabis product is not in substantial compliance if its observed THC potency falls outside 75 percent to 125 percent of the amount printed on the label.

That is the new line. A product labeled at 15 percent THC must test between 11.25 percent and 18.75 percent. If it does not, the state says the item can be placed on administrative hold, which means the inventory is frozen in the state tracking system and cannot keep moving through normal sale channels, and it can be removed from the market until the problem is corrected.

This is news now because the Commission did not present the issue as a distant rulemaking debate. It announced an audit program that will start checking labeled potency against test results and tied that audit directly to enforcement. For operators, that turns THC labeling from a marketing and packaging choice into an immediate inventory risk.

The practical effect is broad. Cultivators, manufacturers, brands, testing labs, wholesalers, and retailers all touch the number that ends up on the package. A mismatch can now create a stoppage after the product is already in circulation. That makes this a compliance story, but also a production planning story and a retail operations story.

The state framed the move as part of a wider effort to improve testing transparency. That matters because it shows the Commission is not only warning companies about labels. It is building a system to compare what laboratories report, what companies print, and what consumers see at the point of sale.

For the broader market, the message is simple. Massachusetts no longer appears willing to treat THC inflation as background noise.

The audit depends on lab results, digital certificates, and a stronger testing record

The new potency audit sits on top of systems the state has been tightening for more than a year. In April 2025, the Commission ordered all licensed Independent Testing Laboratories to upload certificates of analysis into Metrc, the statewide seed-to-sale tracking platform that follows cannabis inventory through the legal market. A certificate of analysis, often shortened to COA, is the lab report that shows what was tested and the result. When those reports are uploaded into the tracking system, regulators can match a product lot to its official test record without relying on paper copies moving between businesses.

That back-office change now looks less administrative than it did at the time. If the state wants to audit the THC printed on a package, it needs a dependable source of test data and a way to connect that data to the exact product in commerce. The COA upload order provided that plumbing. The new bulletin adds the enforcement standard.

The Commission has also been updating and correcting public testing datasets in 2026, and it maintains an open-data catalog and sales and product distribution dashboards. Those pages do not create the enforcement power on their own. What they do show is that Massachusetts is trying to run cannabis oversight with more visible records, more standardized reporting, and more cross-checking between commercial activity and lab data.

That context matters because potency disputes in cannabis are not only about one bad batch or one careless label. The number on a package is a chain of decisions. A cultivator grows material with natural variation between plants and harvests. A manufacturer transforms that material into inhalable products, edibles, or concentrates that may have different testing and labeling conventions. A lab measures THC and often THCA, the acid form that converts into THC when heated, and reports results that may be presented in several ways. Then a brand chooses how to translate that laboratory result into consumer-facing language on the package.

Every step can introduce mismatch. Some mismatch is ordinary biological variation. Some comes from sample handling, batch averaging, or timing. Some comes from the commercial temptation to print the most flattering number that can be defended. Massachusetts has now said the tolerance is not unlimited. The state is willing to treat a wide enough gap as noncompliance.

The bulletin uses the phrase substantial compliance, which is regulatory language for whether a product is close enough to the required standard to remain acceptable. In practical terms, the Commission is saying that a package can no longer drift too far from what the audited result shows and still be treated as good enough.

The same-day Commission release also emphasized the role of the state’s 11 Independent Testing Laboratories. That is important for two reasons. First, the audit is not aimed only at one corner of the supply chain. It depends on the licensed lab network that underpins the whole market. Second, it means labs are being pulled more directly into a commercial dispute that brands and retailers have often handled informally. If the state is comparing labels against lab-backed potency data, the laboratory result becomes a more active enforcement trigger.

That does not mean the science is suddenly simple. Potency testing is still a measurement process applied to agricultural material and manufactured products that can vary by sample, form, and batch. The state has not erased those complexities. It has chosen a compliance band that tells the market how much deviation it will tolerate despite them.

Brands, processors, stores, and labs now share a packaging problem with inventory consequences

The immediate operational consequence is that packaging decisions can no longer be treated as the final cosmetic step before sale. A product label that overstates or materially understates THC now carries a clearer chance of enforcement after distribution. That changes how companies set release procedures.

For brands and manufacturers, the first pressure point is label governance. Many operators have historically treated potency claims as a mix of science, packaging lead times, and commercial instinct. That becomes harder to defend when the state has published a numerical audit range. A product may have passed through required testing and still create trouble later if the label printed for the batch does not align closely enough with the tested result.

That is especially relevant for businesses selling products across multiple batches under the same brand design. If packaging is printed in volume, and potency shifts from lot to lot, the operational convenience of using one standard label can now collide with the audit program. Companies may need tighter batch-specific label controls, faster packaging updates, or more conservative potency claims.

Retailers are affected even when they do not control the test result or the label language. An administrative hold can stop sales of inventory already sitting on the shelf or in the back room. For a store, that means stranded working capital, staff time spent pulling product, and possible customer confusion around missing items. It also means retail buyers may become more selective about which suppliers look operationally reliable, not just which suppliers offer attractive margins or strong sell-through.

Cultivators and processors face a related discipline problem. If product characteristics vary too much between harvests or production runs, the pressure lands downstream on labeling and inventory management. The new audit rule does not tell growers how to grow or processors how to formulate. But it does create a market incentive to reduce avoidable variance before a product reaches testing and packaging.

The laboratory side is more delicate. Massachusetts has not announced that every potency mismatch is a laboratory failure. Nor has it said that a package number automatically proves misconduct. But once the state starts auditing potency labels against test records, laboratories will be drawn into disputes about sampling, methods, consistency, and reproducibility. In plain terms, a bad label now has a clearer path back to the testing record that supported it.

For medical businesses and adult-use businesses alike, the enforcement line matters because label trust is not a niche issue. THC is the number many consumers use to compare products quickly, even when that number is an imperfect guide to effect. If the legal market allows wide slippage between the claimed amount and the observed amount, it weakens one of the basic promises of regulated commerce, which is that the package should describe the product with reasonable accuracy.

The Commission’s broader transparency push adds another layer. Mandatory digital COA uploads, ongoing testing-data updates, and more public-facing publication of THC and THCA results all make it easier for regulators and, over time, the public to see whether outlier numbers cluster around certain products, brands, or labs. That does not mean every data point will be self-explanatory. It does mean the room for opaque handling of potency claims is shrinking.

There are still unresolved points. The Commission has provided the compliance band and the consequence of administrative hold, but some practical details will matter in day-to-day operations. Operators will want to know how samples for audits are selected, how disputes can be handled, whether there will be confirmatory testing in contested cases, how relabeling versus destruction will be treated, and how quickly held inventory can return to sale once corrected. Those are not small procedural questions. They determine whether the program functions as a quality-control tool or becomes a source of recurring commercial friction.

Even with those uncertainties, the direction is already clear. The state is moving potency from a loosely tolerated marketing edge into a monitored claim with traceable records behind it.

The point is not just THC accuracy but whether a regulated market can make its labels believable

Massachusetts is doing something more consequential than setting a tolerance band. It is asserting that the label on a cannabis package belongs inside the enforcement perimeter, not outside it.

That distinction matters because regulated cannabis has long carried a contradiction. The industry often asks to be treated like a serious consumer goods market, with the legitimacy that comes from licensing, testing, and tracked distribution. At the same time, potency numbers have often operated as a competitive theater in which the highest plausible figure draws attention and commercial pressure travels back through the chain. Those two positions do not sit together for long.

By formalizing an audit threshold and tying it to administrative holds and market removal, the Commission is choosing the consumer-goods model over the theater. It is saying that label accuracy is not merely a best practice or an ethical preference. It is part of whether a product remains saleable.

That is a harder line than some operators will welcome, especially in a market where businesses already face margin pressure, slow-moving inventory, and heavy compliance costs. Reprinting packaging, tightening quality systems, and dealing with held stock all cost money. Some companies will argue that natural variation and testing complexity make a fixed percentage band imperfect.

That criticism has some force. Cannabis is not a uniform industrial input, and potency testing is not free from technical judgment. But the alternative is not neutral. The alternative is a market in which one of the main numbers used to sell products can drift too far from the tested result without a clear consequence. Over time, that stops looking like flexibility and starts looking like regulatory indifference.

The Commission’s own recent actions suggest it understands that enforcement without records would be weak and records without enforcement would be performative. That is why the May 22 announcement matters beyond the percentage band itself. It connects laboratory uploads, public data work, and targeted audits into one operational theory of oversight.

For better operators, this may become an advantage. Businesses that already keep tighter batch controls, use more disciplined labeling practices, and avoid stretching potency claims should have less to fear from audits than businesses that built sales strategy around optimistic packaging. The measure does not solve every trust problem in cannabis testing. It does create a clearer dividing line between companies treating the label as a factual statement and companies treating it as a sales surface.

That is where the significance of this move finally rests. Massachusetts is not trying to win an argument about one metric in isolation. It is trying to decide whether the legal market can make a plain promise and keep it. If the package says a product contains a certain amount of THC, the state now expects that claim to survive an audit within a defined range. In a mature regulated market, that should not be an ambitious standard. It should be the minimum one.